<DOC>
	<DOCNO>NCT00122512</DOCNO>
	<brief_summary>This Phase 2a study involve Tenofovir Disoproxil Fumarate ( TDF ) provide extend safety data high-risk men . Secondarily , study assess feasibility conduct trial evaluate preliminary effectiveness TDF 300 mg HIV prevention method take day .</brief_summary>
	<brief_title>Study Tenofovir Disoproxil Fumarate ( TDF ) Prevention HIV</brief_title>
	<detailed_description>TDF select investigation prophylaxis HIV high-risk men unique pharmacologic profile . In addition convenience daily single tablet , TDF ’ safety profile comparable placebo among HIV infect person , strike anti-HIV potency , low potential selection resistant virus . TDF clear body kidney metabolize liver . Therefore , TDF limit potential pharmacokinetic interaction hepatically metabolize drug . Each property necessary give reality intend target population . Moreover , initial prevention study simian model provide encouraging result . Finally , drug ’ sponsor supportive investigate potential use TDF preventive , well therapeutic agent , provide TDF study , willing make good faith effort make TDF available public health use prove effective HIV prevention .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Be willing able give inform consent Be 18 year old Be willing use study product direct Be willing adhere followup schedule Be willing participate study 12 month Be general good health ( active , serious infection require parenteral antibiotic , active clinically significant medical condition , include heart disease , diabetes , asthma , alcoholism , cancer ) Meet least one three high risk criterion : *Sex sex worker/bar girl last 3 month ; Sex 2 woman last 3 month ; Sexually transmit disease ( STD ) last 3 month Have absence HIV antibody rapid test ( screen enrollment visit ) Have absence hepatitis B ( HB ) surface antigen ( sAg ) Have adequate renal function ( serum creatinine &lt; 1.5 mg/dL ) Have adequate liver function ( hepatic transaminase ( ALT &lt; 54 U/L AST &lt; 46 U/L ) Have adequate serum phosphorus ( &gt; 2.2 mg/dL ) Not intend relocate area duration study participation job obligation may require long absence area Not receive experimental HIV vaccine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>TDF tenofovir disoproxil fumarate , GS-4331-05 , PMPA prodrug</keyword>
	<keyword>µg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>